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Abstract
SmartLipids are the latest generation of dermal lipid nanoparticles with solid particle matrix. Their characteristic properties result-
ing from the “chaotic” and disordered particle matrix structure are reviewed. These properties are high loading and firm inclusion
of active agents, physical stability of the particle matrix lipid modification (primarily α, β′), and related to these three properties the
improved chemical stabilization of labile active agents. Exemplarily data for these effects are shown and underlying mechanisms
are discussed. Further, general properties of lipid nanoparticles, which are also exhibited by the SmartLipids, are reviewed. These
include the restauration of the protective lipid skin barrier (anti-pollution effect), penetration enhancement by occlusion (invisible
patch effect) and the option to control the release of active agents for optimized biological effect and reduction of side effects (e.g.,
skin irritation through sensitizing active agents), which improves the skin tolerability. Regulatory aspects, such as submicron parti-
cle status, excipients, and certifications, are also discussed.
Introduction
To meet the increasing expectations and demands of consumers
in personal care and cosmetics, as well of patients in medical
care, dermal delivery systems are needed to improve the perfor-
mance of dermal formulations. There are also requirements
from the formulation manufacturer regarding perfected delivery
systems. The primary requirements for an optimized carrier
system are:
1. Sufficiently high loading capacity allowing for the
utilization of low amounts of carrier, so as to not
distinctly affect the properties of the formulation, e.g.,
skin feeling;
2. physical stability, i.e., firm inclusion of active agents and
remaining integrity of the carriers in the final formula-
tion during shelf life;
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3. effective protection and stabilization of chemically labile
active agents, e.g., retinol as a classical example;
4. restoration of the natural skin barrier (recently in focus in
the framework of “anti-pollution” strategies);
5. penetration enhancement and increased bioavailability
allowing for a reduced application frequency, enabling
the use of active agents that could not be used before due
to lack of penetration, e.g., certain antioxidants;
6. controlled and prolonged release in order to avoid too
high concentrations on the skin that may cause irritancy
(e.g., retinol and tretinoin);
7. composition preferentially of natural or naturally derived
and modified raw materials that are ideally biodegrad-
able and in conformity to ECOCERT/COSMOS (e.g.,
natural lipids or semisynthetic lipids derived from
natural lipids).
Emulsions can only partially meet these requirements. For ex-
ample, the protection of chemically lipophilic active agents is
limited by the diffusional exchange with water. Controlled
release is not possible due to the high diffusion coefficient, D,
in oils of low viscosity (Einstein equation). Release typically
takes place very fast within seconds or milliseconds [1]. The
age of smart delivery systems for skin started with the introduc-
tion of liposomes to the cosmetic market in 1986 from the
company Dior with the product Capture. Liposomes have
several advantages for dermal delivery, e.g., adhesiveness to
skin due to the small nanometric size, increase of skin moisture
related leading to wrinkle reduction, and a stabilization of
active agents to some extent.
In the following years attempts were made to come up with
better delivery systems of the next generation. Looking back,
these efforts were of limited or no success. For example, many
expectations were raised with dermal microemulsions. Howev-
er, the need of relatively high surfactant concentrations (skin
irritating/damaging effects) and the often unpleasant applica-
tion feeling did lead to a market failure. Polymeric nanoparti-
cles, developed by P. P. Speiser for pharmaceutical purposes in
the middle of the 1970s [2], found only limited use in consum-
er care/cosmetics. Problems are often the lack of regulatory
status of many polymers used, expensive large-scale produc-
tion and the lack of biodegradability (no “green” products
possible, thus no certification after ECOCERT/COSMOS).
There were also developments of various “somes”, being
derived from the liposomes and finding few applications (e.g.,
niosomes, ethosomes, transfersomes, pharmacosomes, herbo-
somes, colloidosomes, sphinosomes and cubosomes [3].
A step forward in 1991 was the development of a carrier made
from solid lipids, the solid lipid nanoparticles (SLNs). They are
derived from the emulsions by replacing the liquid lipid (oil)
with a solid lipid and therefore are solid at body temperature.
The second generation of these particles, the nanostructured
lipid carriers (NLCs), made it to the cosmetic market in 2005
and are typically a mixture of one solid lipid and one liquid
lipid [4], e.g., tristearin and caprylic/capric triglyceride, also
being solid at body temperature.
In 2014 a new generation of carriers was developed, called
SmartLipids [5,6]. They combine all the existing advantages of
the previous particles made from solid lipids/lipid blends and
add new key features. These are distinctly increased loading
capacity and firm inclusion of the active agents, together with
improved physical stability and increased chemical stabiliza-
tion. This was achieved by creating a “chaotic” matrix structure
by blending many different lipids, e.g., up to ten solid lipids, or
mixture of solid and liquid lipids [7]. The structure of the
SmartLipids and related key advantages are discussed. Briefly
reviewed are the properties of SmartLipids originating from
being solid lipid particles, i.e., possessing the same beneficial
properties as abovementioned SLNs and NLCs. Industrial
aspects such as regulatory issues and technical questions are
covered regarding the production of marketable products in
cosmetics and consumer care.
Review
What exactly are SmartLipids – definition
SLN were made from typically one solid lipid only. Such lipids
can form highly ordered lipid crystalline structures (β modifica-
tion), which leaves little space to accommodate active agents
and limits its loading capacity. Sometimes expulsion of the
active agent takes place during storage, when the lipid re-orders
from α and/or β′ modification to primarily β modification. To
overcome the loading limitation in NLCs, oil was admixed to
the solid lipid, since liquid lipids (oils) exhibit higher solubili-
ties for active agents compared to solid lipids. In NLCs, the
solubilities of solid and liquid lipid are approximately additive,
i.e., the solubility of active agents in the NLC particle blend is
increased. However, the increase comes at the expense of an
accelerated reordering during storage, as oils can accelerate the
transition process to the β modification.
In the SmartLipids principle many structurally very different
lipids (typically up to ten) are blended on purpose, being
spatially incompatible due to differences in structure (mixture
of mono-, di and triglycerides, or waxes) and length of the fatty
acid chains. This was achieved by blending solid lipids only
(e.g., with chains C14–C22), or by admixing limited amounts of
oils (e.g., containing C8–C12 fatty acids). This leads to a lipid
particle matrix structure being primarily or to a considerable
extent in α modification with some β′ modification, having
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many imperfections for an enhanced loading capacity of active
agents (Figure 1). Due to the structural differences of the lipid
molecules, reordering during storage to the highly ordered β
modification is blocked or distinctly slowed down. Thus, no
expulsion of active agents takes place leading to firm inclusion.
The addition of oils increases the loading capacity further, but
oil addition needs to be limited in order to prevent an acceler-
ated reordering of the lipid matrix.
Figure 1: Simple representation of the structure of SmartLipids. The
mixture of structurally very different solid and liquid lipids leads to a
chaotic, less ordered structure (α, β′) with many imperfections, provid-
ing high loading capacity. The structure remains unchanged during
storage leading to a firm inclusion of active agents with chemical stabi-
lization and no expulsion of the active agents [10].
Some of the previously described NLC particles already repre-
sent the “SmartLipids principle”. This is the case when the one
solid lipid used in the mixture of one solid/one liquid lipid is a
commercial lipid that is already a blend of multiple lipids, or
when it is a priori a “wild mixture” of different structures, e.g.,
carnauba wax, mostly consisting of aliphatic esters (40.0 wt %),
diesters of 4-hydroxy cinnamic acid (21.0 wt %), ω-hydroxy
carboxylic acids (13.0 wt %) and fatty acid alcohols
(12.0 wt %). The chain length of fatty acids and alcohols is
mainly in the range of C26–C30 [8]. Another classical example
of a commercial lipid blend is Cutina LM, which is composed
of three pure lipids and three natural lipid mixtures (cetearyl
alcohol, cetearyl glucoside, octyldodecanol, carnauba wax,
candelilla wax, and beeswax). Different from the SmartLipids
principle are, e.g., NLCs made from a relatively uniform solid
lipid, e.g., tristearin (mainly C18 triglyceride) blended with
caprylic/capric triglyceride [9].
Dermal application – main key features of
SmartLipids
High loading capacity and firm inclusion of active
agents
The unordered “chaotic” matrix state of SmartLipids provides
enough defects to accommodate distinctly higher amounts of
active agents compared to SLNs and NLCs. This can be seen
regarding the maximum loading achieved for retinol and lido-
caine (Figure 2). In this case the loading increases by a factor of
about 15 and 3, respectively.
Figure 2: Maximum loading reported for SLNs, NLCs and SmartLipids
for the dermal active agents retinol [11-13] (left) and lidocaine [14]
(right).
The higher loading capacity ensures the firm inclusion of the
active agent as well. In NLCs it was sometimes necessary to in-
corporate, e.g., 5% retinol (= maximum loading) to achieve the
desired retinol concentration in the final product. At the
maximum loading capacity, reordering could cause the expul-
sion of the active agent into the water phase (crystal formation).
This is not the case in SmartLipids, since the maximum loading
capacity is increased to 15. Even slight reordering will not lead
to active expulsion when lower loadings than the maximum
possible are employed. Of course, the degree of loading affects
also the release (cf. section 3.4).
Physical stability in products
The aspects of physical stability in lipid particle dispersions
during storage and in final products are (1) an unchanged crys-
talline structure of the particle matrix and (2) the quantitative
proof of remaining existence/presence of particles. The created
crystalline structure should primarily remain in the unordered
state for firm inclusion of loaded active agents, which can be
measured by combining differential scanning calorimetry
(DSC) with X-ray diffraction. Ruick showed a fast transition
from the α modification to the β modification when SLNs were
produced with tristearin (Figure 3), while a SmartLipids mix-
ture with eight solid lipids remained practically unchanged
during one year of storage.
Carriers, especially fluid carriers such as liposomes, can reduce
in number in a final product during shelf life. Liposomes have a
tendency to fuse with the stabilizer layers of oil droplets in oil/
water creams. For the best quality, the quantitative stability of
the carriers is desirable. Especially, quantitative stability is re-
quired in case of pharmaceutical formulations. Quantitative
analysis of, e.g., liposomes in final products is relatively diffi-
cult, but required in some countries from regulatory authorities.
The difficulty of such analysis was tried to circumvent, e.g., by
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Figure 3: X-ray diffraction patterns of SLNs (pink curve) and SmartLipids mixture (red curve) determined directly after production and after one month
(SLNs: blue curve) and one year (SmartLipids: black curve) storage at room temperature [5].
only specifying “lecithin” in the product, despite knowing that a
main contribution of the product performance is coming from
the existing liposomes formed by lecithin. In contrast, the quan-
titative proof of 100% existing lipid particles with solid particle
matrix is very easy by measuring the melting enthalpy using
differential scanning calorimetry (DSC). The melting enthalpy
of a SmartLipids suspension can be determined before addition
to the product, after addition to a gel or a cream and after
storage. In case the particles dissolve, e.g., in an oil of a cream,
the melting enthalpy will decrease. Thus, the physical stability
of SmartLipids is easy to analyze and to prove.
Chemical stabilization of active agents
Classical fluid carriers such as nanoemulsion and liposomes
have a limited ability to protect labile lipophilic active agents.
Due to the partitioning coefficient, K, after Nernst, the
lipophilic active agents are primarily enriched in the lipid phase
and only to a small extent in the water phase. But there is a
diffusional exchange between the oil and the water phase. The
active agent diffuses from the oil into the water phase, the
active agent is degraded in the water phase (e.g., hydrolyzed),
the degraded active agent diffuses back into the oil phase and is
replaced in the water phase by new non-degraded active agent
from the oil. This is a kind of vicious circle (Figure 4, right).
Due to the relatively low viscosity, η, of oil (70–100 mPa·s) and
phospholipid bilayers (184 mPa·s [15]), this process takes place
relatively fast. The diffusion coefficient D can be calculated
using the Einstein equation:
with kB being the Boltzmann constant and T being the absolute
temperature. In contrast, the viscosity η in solid particles is very
high, e.g., 653 mPa·s for solid paraffin. Thus, the abovemen-
Figure 4: Fast degradation of lipophilic active agents (R) in fluid
carriers (blue), such as oil/water emulsions or creams and liposomes,
through fast exchange with the water phase (right) in comparison to a
minimized exchange of active between a highly viscous solid carrier
(red) and the water phase (left) (P: partitioning coefficient); modified
with permission from [17], copyright 2017 Elsevier.
tioned exchange is practically avoided or at least strongly mini-
mized [16] (Figure 4).
Retinol is a chemically highly labile molecule, and thus the effi-
cient stabilization in dermal products is a challenge. Retinol
was incorporated into various carrier systems, but only with
limited increase in stability. Stabilities reported were 20% after
ten days in liposomes [18], 40% after 24 h in a nanoemulsion
[19], 50% after 24 h in zein colloidal particles [19] and 60%
after one month in a nanoemulsion stabilized by silica [20]. A
screening was performed in two SmartLipids mixtures. The
solid particle matrix itself is protective for labile molecules as
outlined above. Up to 86% retinol remained after six months of
storage at room temperature (Figure 5, lower right). This stabi-
lization is due to the solid character of the carrier matrix with
limited exchange of active agent with the water phase, and the
protection of the active agent inside the solid carrier matrix,
e.g., against access of oxygen and light. To have an even better
stabilized system, lipophilic anti-oxidants were added leading to
about 85–95% retinol remaining at room temperature (Figure 5,
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Figure 5: Storage study with retinol loaded SmartLipids particles over six months. Remaining retinol content in SmartLipids formulation P (left) and R
(right) before and after incorporation of lipophilic antioxidants Tinogard TT and BHT at 40°C (upper) and room temperature (25°C, lower), [10].
lower row), and 65–70% at a stress temperature of 40 °C
(Figure 5, upper row). More complex particle structures of
SmartLipids lead to better incorporation and protection of
active agents.
Size of SmartLipids submicrometer particles – legal
aspects
By definition, nanoparticles possess a size in the nanometer
range, i.e., from a few nanometers to below 1000 nm. Legally,
after the EU cosmetic guideline [21], nanoparticles are only
particles with a size below 100 nm, precisely a particle popula-
tion with more than 50% of the particles below 100 nm based
on the number distribution. Incorporating a nanoparticle materi-
al needs to be declared in the INCI nomenclature by the addi-
tion of “nano”.
A typical mean size of SmartLipids particles is in the range of
200–400 nm, measured by laser light scattering, i.e., photon
correlation spectroscopy (PCS). The calculated size is based on
the intensity signal of the scattered laser light, which is used to
calculate a so-called correlation function g(τ). The obtained
mean diameter is the intensity-weighted so-called z-average
(z-ave). The correlation function g(τ) can be converted to a size
distribution by Fourier transformation. EU regulations require a
measuring method that can cover the full size range of a parti-
cle population. The measuring range of PCS is roughly from
about 3 nm to 6 µm. Suspensions of SmartLipids do not contain
particles below 3 nm, and practically no, or only negligible
contents of, particles larger than 6 µm. Thus, PCS is a suitable
method to meet the EU requirements for SmartLipids products.
The absence of particles above 6 µm could be proven by laser
diffraction (Malvern Mastersizer 2000, Malvern, UK). In this
case the volume distribution was taken, because it is more
sensitive to show a few large particles than the number distribu-
tion.
To avoid the linguistic confusions: technically the particles are
nanoparticles but at the same time are legally not nanoparticles.
Those particle populations should be classified as “submicrom-
eter particles”. Submicrometer particles are in the size range be-
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Figure 6: Left: Nile red-labeled lipid nanoparticle suspension (right arm) and nanoemulsion (left arm) applied to human forearm directly after applica-
tion. Right: Both arms after washing under flowing water with rubbing. The lipid nanoparticles are highly adhesive and mostly remain on the skin (right
arm).
tween 100 nm and 1000 nm, nanoparticles are smaller than
100 nm. Hence, SmartLipids are submicrometer particles.
Industrial production of SmartLipids - standard &
customized products
The production of SmartLipids is identical to that of SLNs and
NLCs [22]. The lipid mixture is heated to approximately
5–10 °C above the melting point of the highest melting lipid,
then the active agent is dissolved in the lipid melt and the melt
containing the active agent is dispersed in a hot aqueous stabi-
lizer solution (surfactant, polymer) of identical temperature by
high-speed stirring to form a coarse emulsion. This pre-emul-
sion is then passed through a high-pressure homogenizer, and
typically one or two homogenization cycles are applied.
Homogenizers used are typically piston–gap homogenizers,
e.g., the APV Gaulin 5.5. homogenizer with a production
capacity of up to 150 L/h (medium scale) [7], and the GEA Niro
Soavi homogenizer with production capacities of up to
10.000 L/h (large scale). The obtained hot nanoemulsion is
cooled, the lipid blend re-crystallizes and forms solid lipid par-
ticles. The suspensions are preserved by standard preservatives
(e.g., euxyl® PE 9010) or are alternatively prepared preserva-
tive-free by adding, e.g., pentylene glycol. Standard products
are available on the market, while coenzyme Q10 and retinol
are in preparation. Formulations with customer-specific active
agents can also be prepared on an exclusive basis. Concentrates
have a typical particle content of 10% or 20%. For the incorpo-
ration into cosmetic products, the dermal formulations are pro-
duced as normal, but with slightly reduced water content. At the
end of the production, the SmartLipids concentrates are
admixed under blending with a stirrer.
Dermal application – general features of lipid
nanoparticles with solid particle matrix
Adhesion onto skin with increased residence time/
prolonged release
There are many properties that are identical for the several
types of lipid nanoparticles – SLNs, NLCs and SmartLipids –
because they only depend on physical characteristics (e.g., par-
ticle size or general adhesiveness of small particles) or chemi-
cal characteristics (e.g., nature of the particle material, in this
case lipid). Thus, data published previously regarding these
general features also apply to the newly developed SmartLipids
particles.
It is well known that decreasing the particle size leads to a
larger interaction area between particles and substrate and
thereby the adhesiveness increases. The classical and often cited
example from food industry is the different adhesiveness of
crystalline sugar and icing sugar onto bakery products. Large
crystals tend to fall off, whereas icing sugar forms sticky layers
on bakery products. Thus, all nanoparticles, e.g., as reported for
liposomes [23,24], have an increased adhesiveness to skin. In a
recent study it could be shown that the adhesiveness of solid
lipid particle suspensions to human skin is superior to fluid
nanoemulsion droplets. Both, similar in size, were labeled with
Nile red and applied in a square onto the inner forearm. The
presence of applied particles was detected using an UV lamp
with a wavelength of 365 nm (Figure 6, left). Then the fore-
arms were washed under flowing water and rubbed with the
thumb. Most of the nanoemulsion was washed off, whereas the
lipid particles mostly remained on the skin (Figure 6, right).
This increased adhesiveness and related residence time on the
skin promotes a prolonged release of active agents, especially
when sweating occurs with subsequent tissue wiping by the
consumer or when skin areas are covered with clothes.
Restauration of the natural skin barrier and
anti-pollution effect
Due to unhealthy skin conditions or general stress by environ-
mental factors, the natural skin barrier (lipid film on the stratum
corneum) can be damaged, i.e., thinned or even partially lost
(bare patches). This has negative effects on the cells below and
could lead to a higher transepidermal water loss (TEWL). In ad-
dition, the skin is more exposed to environmental stress,
ranging from UV/IR radiation to pollution from the air, e.g.,
Beilstein J. Nanotechnol. 2019, 10, 2152–2162.
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Figure 7: Determination of the relative film thickness by measuring the
dielectric constant D on skin. Probe readings of untreated skin and
skin with applied increasing concentration of lipid particle suspension;
reproduced with permission from [27], copyright 2013 Euro Cosmetics.
particulate matter. Especially in the last two years, skin care
products/cosmetics with “anti-pollution” effect are a key topic.
Cosmetic formulations can reduce the adsorption of particulate
matter onto the skin and minimize related negative skin effects.
Thus, the effective restauration of the skin barrier is an impor-
tant feature of lipid nanoparticles [25], and a long residence
time of the particles on the skin even under mechanical stress is
beneficial to fight pollution factors.
The lipid particles adhere onto the skin as any nanosized parti-
cle does and form a film. This film formation can be followed
by measuring the dielectric constant of the skin, using a
Corneometer® (Courage + Khazaka Electronic GmbH,
Germany) [26]. The probe determines the dielectric constant, D,
of the skin through a condenser in the probe. An insulator medi-
um in the condenser reduces the measured D value. For exam-
ple, D is 0 for a complete insulator (vacuum), about 5 for lipids
and organic liquids, and 80 for pure water. The reading is given
in arbitrary units. If the skin moisture increases through the ap-
plication of a cosmetic cream, the obtained D value increases.
However, if an insulator material is between the probe and the
skin (i.e., a lipid film), the D value decreases (Figure 7, lower
row). This was shown in [27,28]. Applying a lipid particle film
to the skin led to the formation of a lipid layer thicker than the
normal barrier, resulting in D values below the D values of the
normal lipid film on skin (Figure 7, upper row). The thickness
of the created lipid film by applying lipid particle suspensions is
controlled by the particle concentration in the suspension. The
formation of a film can also be concluded by measuring the de-
crease in transepidermal water loss (TEWL) after application of
the lipid particles in a formulation.
Following this model, any lipid particle can be used to repair
the stratum corneum film, independent on its lipid composition
and loaded active agent, as it was the case in [27,28]. Restaura-
tion of the natural lipid barrier is thus a beneficial effect gener-
ated already by unloaded SmartLipids on the skin. Also,
ceramides can be used to produce SmartLipids, albeit primarily
for the higher priced cosmetic sector.
Increased penetration and bioavailability
Occlusion increases the dermal penetration of many active
agents. Occlusion leads to increased moisture content of the
skin as well as increased percutaneous absorption of most active
agents [29,30]. A simple but efficient way to obtain occlusion
in the hospital is to cover a cream-treated skin area with a
plastic foil. Pharmaceutical transdermal patches benefit also
from the occlusion effect of their polymer films, promoting
penetration. However, such patches are of no or limited use for
facial cosmetics. A compromise is to apply cosmetic masks for
a limited time, requiring consumer patience and compliance to
the regular treatment. In contrast, lipid particle formulations are
described in the literature as “invisible patch” [27]. After being
applied to the skin, they show controlled occlusive and delivery
effects comparable to patches (or some masks) but are “invis-
ible” and thus create their effect up to 24 h. Increased penetra-
tion of active agents due to occlusion is extensively described in
the literature [29].
To show the ability of SmartLipids to provide efficient skin
penetration, a particle suspension was prepared containing 0.2%
curcumin. Curcumin has many positive effects on the skin
[31,32] and is at the same time fluorescent, allowing for a good
and easy detection in the skin by fluorescence microscopy. The
suspension was applied to pig ear skin in a covered Franz cell,
incubated for 24 h and then skin slices were investigated by
normal light and fluorescence microscopy (Figure 8, left
column). Figure 8 (upper row) shows the fluorescence micros-
copy images. The lower row shows overlays of fluorescence
and light microscopy images, allowing to locate the fluores-
cence in the epidermis. For comparison, a tenfold higher
concentrated 2% curcumin suspension is shown in Figure 8
(middle column). The curcumin remains as a thick fluorescent
layer on top of the stratum corneum, showing practically no
fluorescence inside the epidermis. Finally, a curcumin contain-
ing marketed product from the US is shown, according to
HPLC analysis containing 0.0001% curcumin in dissolved
form, corresponding to its maximum solubility. Only negligible
fluorescence in the skin was detectable (Figure 8, right column).
This shows that SmartLipids are an enabling technology to
provide efficient skin penetration even for such problematic,
poorly soluble active agents such as curcumin. This increased
bioavailability in the skin enables real skin effects.
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Figure 8: Penetration of curcumin into pig ear skin, vertical pig ear slices, fluorescence microscopy images (upper row) and overlay of fluorescence
and light microscopy images (lower row); after application of 0.2% curcumin suspension in SmartLipids (left column), 2.0% curcumin micrometer-size
crystal suspension (middle) and a commercial curcumin containing gel product (right). Incubation time was 24 h. Both laser strength (35%) and fluo-
rescence detector gain (720 V) were kept constant during all measurements.
This study based on curcumin fluorescence was a qualitative
study as the fluourescence intensity was not measured quantita-
tively. However, strong fluorescence (SmartLipids), limited
fluorescence (suspension) and practically no fluorescence
(marketed product) show clear differences. The comparison
with the marketed product was meant to show that there is an
urgent need for improved dermal curcumin formulations. It
should be kept in mind, that both the SmartLipids and the
micrometer-crystal formulation contained a mixture of non-dis-
solved curcumin and curcumin dissolved in the outer phase of
the dermal formulation. The non-dissolved curcumin acts as a
depot to replace the curcumin in the formulation penetrating the
skin. This is the way, how the formulations work, and the
SmartLipids work better.
Controlled and prolonged release
Optimized performance of active agents might depend strongly
on the rate of their release from the carrier. Desirable release
might be fast, prolonged/sustained or should be as slow as
possible (even to no release at all). That means, a carrier system
should provide the ability to control the release of active agents.
A prolonged release is desirable in many formulations, e.g., in
anti-aging compounds such as retinol. A controlled release is
also desirable for active agents having a skin irritation potential,
because concentrations that are too high and promote irritation
need to be avoided. It was shown for tretinoin, that incorpora-
tion into lipid particles avoided skin irritation [33]. Little or no
release is ideal for molecular sunscreens for UV protection,
which should not penetrate into but remain on the skin, ideally
inside the carrier, to generate their protective effect. At best,
they should remain inside the lipid particle, since it was shown
that there is a synergistic effect of the particle matrix on the mo-
lecular sunscreen increasing its protective efficiency [34]. This
allows the reduction of molecular sunscreen concentration in a
product.
The release can be controlled by the localization of the active
agent inside the solid lipid particle matrix. Without going into
technical details, the localization of the active agent can be
modified by the composition of the lipid particle matrix, con-
centration of active agent and production parameters. A very
fast release is generated, when the active agent is primarily lo-
cated in the outer shell of the particles (enriched shell model), a
prolonged release when the active is evenly distributed throug-
hout the whole carrier matrix (solid solution model), and a very
slow/strongly delayed release when the active is mainly located
Beilstein J. Nanotechnol. 2019, 10, 2152–2162.
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Figure 9: Models of cosmetic active agents or drugs (green) incorporated into lipid nanoparticles, from left to right: enriched shell model (fast release),
solid solution model (prolonged release) and enriched core model (very slow release); reproduced with permission from [17], copyright 2017 Elsevier.
Figure 10: Examples of release profiles from lipid nanoparticles: very fast release of cyclosporine within minutes (upper row, after [35]), and the other
extreme of very slow release of prednisolone over 35 days (lower row, after [36], explainable by enriched shell and enriched core model, respectively.
in the core (enriched core model) (Figure 9). For example, a
very fast and complete release within minutes was shown for
cyclosporine (Figure 10, upper row) [35], and an extremely
prolonged release of only 37.1% of prednisolone after 5 weeks
was achieved with solid lipid nanoparticles (Figure 10, lower
row) [36] The distinctly reduced side effects of tretinoin re-
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leased from lipid nanoparticles can be explained by a con-
trolled release, avoiding high peak concentrations of free
tretinoin on the skin.
In dermal sunscreen formulations, the lipophilic sunscreens are
normally dissolved in the oil phase of oil/water emulsions. Due
to the liquid state of the oil droplets, the evenly and molecu-
larly dispersed sunscreen within the droplets can be released
quickly and penetrate into the skin. The release of oxybenzone
from an emulsion and SLNs was compared in an in vitro Franz
cell model. The release from emulsions was two times faster
(Figure 11) [37]. The distinctly slower release from the lipid
nanoparticles shows their potential of reducing undesired side
effects by large amounts of sunscreen penetrating into the skin.
Figure 11: In vitro release of the sunscreen oxybenzone from a
nanoemulsion (grey) and from a SLN suspension (black) measured in
Franz diffusion cells, after [37].
Conclusion
The lipid nanoparticle history started in 1991 with SLNs, the
second generation of NLCs entered the cosmetic market just
14 years later in 2005, much faster than the liposomes did (they
needed about 20 years from invention to cosmetic market in
1986). With the “SmartLipids concept” a mature industrial
delivery system is available since 2016. The outstanding fea-
ture is the number of delivery advantages combined in one
single system. Specific to SmartLipids are:
1. High loading capacity,
2. firm inclusion of active agents,
3. physical stability of the carrier in the final formulation
(and easy to prove) and thus
4. improved chemical stabilization of active agents.
General features of all lipid nanoparticles are the restauration of
the natural protective lipid barrier, and penetration enhance-
ment with increased dermal bioavailability and controlled/opti-
mized release.
Even if a different carrier system is superior in one or two prop-
erties, the sum of the combined delivery advantages in
SmartLipids outweighs this in most cases. On top, to meet
upcoming consumer expectations, conformity to ECOCERT/
COSMOS can be provided and the particles are not nanosized
but submicrometer carriers. Contract manufacturing on indus-
trial scale under GMP is available, also for customized formula-
tions. Thus, the basis for broad use in cosmetics and consumer
care products is given.
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